Nagaprasad Nagajothi, MD
Hematology & Oncology · Massillon, OHNPI 1780612333
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,887 of the $26,339 with a category attached, or 67.9%. 60 manufacturers reported payments, led by Sanofi at 25.8% of the total. Reporting peaked in 2019 at $9,545 and has fallen 63.8% since, to $3,453 in 2025.
Across 991 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- Tosoh Bioscience, Inc.$2K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Merck$1K
- Johnson & Johnson$819
- plus $13K from 54 others
Across 254 payments — averaging $2900.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Bioscience Inc.$435K
- Merck$134K
- Sanofi US Services Inc.$51K
- Jazz Pharmaceuticals Inc.$49K
- Incyte Corporation$18K
- Morphosys AG$14K
- plus $35K from 5 others
What the payments were for
- Consulting fees$6,37524%
- Food & beverage$17,88768%
- Education$4032%
- Gifts$1,6746%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,339 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 123 | $1,649,104 |
| RevlimidLenalidomide | 60 | $1,094,672 |
| KisqaliRibociclib Succinate | 64 | $1,008,575 |
| IbrancePalbociclib | 55 | $872,848 |
| ImbruvicaIbrutinib | 56 | $854,908 |
| VerzenioAbemaciclib | 54 | $824,359 |
| XtandiEnzalutamide | 49 | $665,392 |
| BrukinsaZanubrutinib | 42 | $630,296 |
| CalquenceAcalabrutinib Maleate | 40 | $587,483 |
| Somatuline DepotLanreotide Acetate | 55 | $485,706 |
| CabometyxCabozantinib S-Malate | 17 | $440,199 |
| Abiraterone Acetate | 71 | $389,425 |
| VenclextaVenetoclax | 49 | $361,300 |
| TukysaTucatinib | 19 | $348,414 |
| PomalystPomalidomide | 13 | $293,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Mekinist, Tafinlar | $1,192 | $1,368,21388 claims |
| PfizerIbrance, Octagam, Eliquis | $733 | $1,283,456347 claims |
| Bristol Myers SquibbRevlimid | $689 | $1,094,67260 claims |
| AstraZenecaCalquence, Tagrisso, Lynparza | $777 | $1,054,83469 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $504 | $854,90856 claims |
| Lilly USA, LLCVerzenio | $348 | $824,35954 claims |
| Astellas Pharma US IncXtandi | $569 | $665,39249 claims |
| Beigene USA, Inc.Brukinsa | $83 | $630,29642 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Alunbrig | $321 | $500,06333 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $173 | $485,70655 claims |
| Exelixis Inc.Cabometyx | $194 | $440,19917 claims |
| AbbVieVenclexta | $340 | $361,30049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Massillon
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.